Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review
Objective: This study systematically reviews health economic evaluations of influenza vaccines in China and synthesizes the evidence on different vaccine categories. Methods: We searched databases, including the China Hospital Knowledge Database, Wanfang, PubMed, Web of Science, and Embase, for stud...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/3/332 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850088126388633600 |
|---|---|
| author | Fanxu Kong Li Cai Jiayi Zhang Huijie Zhu Zhibin Peng Jiandong Zheng Yaming Zheng Hai Fang |
| author_facet | Fanxu Kong Li Cai Jiayi Zhang Huijie Zhu Zhibin Peng Jiandong Zheng Yaming Zheng Hai Fang |
| author_sort | Fanxu Kong |
| collection | DOAJ |
| description | Objective: This study systematically reviews health economic evaluations of influenza vaccines in China and synthesizes the evidence on different vaccine categories. Methods: We searched databases, including the China Hospital Knowledge Database, Wanfang, PubMed, Web of Science, and Embase, for studies on the health economics of influenza vaccines in China from 2015 to 2024. Studies were selected based on predefined criteria, and relevant data were extracted for analysis. The research utilized a parameter, ICER/threshold, defined as the ICER divided by the GDP per capita, to compare the results of cost-effectiveness analysis (CEA) studies. Results: A total of 1743 articles were identified, of which 25 met the inclusion criteria for full-text review. These included 19 Chinese studies and 6 English studies. Study populations were predominantly older adults (52.0%), followed by children, adolescents, people with chronic disease, and pregnant women. Vaccination strategies included trivalent inactivated influenza vaccine (TIV), quadrivalent inactivated influenza vaccine (QIV), trivalent live-attenuated influenza vaccine (LAIV), and non-vaccination groups. For TIV, 94.7% reported positive cost-effectiveness or cost-benefit results, with 21.1% identifying it as the most dominant strategy. For QIV, six studies compared it with a non-vaccinated group, and five (83.3%) reported favorable economic results. The study on LAIV showed cost-effectiveness compared to no vaccination, but not compared to QIV. The ICER threshold for TIV is the most favorable, and the population that exhibits the highest cost-effectiveness and benefit from vaccination is those people with underlying health conditions. Conclusions: TIV vaccination is often cost-effective, especially for people with chronic diseases, children, and older adults. Prioritizing TIV vaccination for those people with chronic diseases is recommended. |
| format | Article |
| id | doaj-art-e184d0d1ad6a401d8ae0ed55b432229a |
| institution | DOAJ |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-e184d0d1ad6a401d8ae0ed55b432229a2025-08-20T02:43:05ZengMDPI AGVaccines2076-393X2025-03-0113333210.3390/vaccines13030332Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic ReviewFanxu Kong0Li Cai1Jiayi Zhang2Huijie Zhu3Zhibin Peng4Jiandong Zheng5Yaming Zheng6Hai Fang7Chinese Field Epidemiology Training Program, Chinese Center for Disease Control and Prevention, Beijing 100050, ChinaDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaDivision of Infectious Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaChina Center for Health Development Studies, Peking University, Beijing 100191, ChinaObjective: This study systematically reviews health economic evaluations of influenza vaccines in China and synthesizes the evidence on different vaccine categories. Methods: We searched databases, including the China Hospital Knowledge Database, Wanfang, PubMed, Web of Science, and Embase, for studies on the health economics of influenza vaccines in China from 2015 to 2024. Studies were selected based on predefined criteria, and relevant data were extracted for analysis. The research utilized a parameter, ICER/threshold, defined as the ICER divided by the GDP per capita, to compare the results of cost-effectiveness analysis (CEA) studies. Results: A total of 1743 articles were identified, of which 25 met the inclusion criteria for full-text review. These included 19 Chinese studies and 6 English studies. Study populations were predominantly older adults (52.0%), followed by children, adolescents, people with chronic disease, and pregnant women. Vaccination strategies included trivalent inactivated influenza vaccine (TIV), quadrivalent inactivated influenza vaccine (QIV), trivalent live-attenuated influenza vaccine (LAIV), and non-vaccination groups. For TIV, 94.7% reported positive cost-effectiveness or cost-benefit results, with 21.1% identifying it as the most dominant strategy. For QIV, six studies compared it with a non-vaccinated group, and five (83.3%) reported favorable economic results. The study on LAIV showed cost-effectiveness compared to no vaccination, but not compared to QIV. The ICER threshold for TIV is the most favorable, and the population that exhibits the highest cost-effectiveness and benefit from vaccination is those people with underlying health conditions. Conclusions: TIV vaccination is often cost-effective, especially for people with chronic diseases, children, and older adults. Prioritizing TIV vaccination for those people with chronic diseases is recommended.https://www.mdpi.com/2076-393X/13/3/332influenza vaccinehealth economic evaluationsystematic reviewChina |
| spellingShingle | Fanxu Kong Li Cai Jiayi Zhang Huijie Zhu Zhibin Peng Jiandong Zheng Yaming Zheng Hai Fang Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review Vaccines influenza vaccine health economic evaluation systematic review China |
| title | Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review |
| title_full | Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review |
| title_fullStr | Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review |
| title_full_unstemmed | Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review |
| title_short | Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review |
| title_sort | comparative analysis of health economic evaluations for different influenza vaccines and vaccination strategies in china a systematic review |
| topic | influenza vaccine health economic evaluation systematic review China |
| url | https://www.mdpi.com/2076-393X/13/3/332 |
| work_keys_str_mv | AT fanxukong comparativeanalysisofhealtheconomicevaluationsfordifferentinfluenzavaccinesandvaccinationstrategiesinchinaasystematicreview AT licai comparativeanalysisofhealtheconomicevaluationsfordifferentinfluenzavaccinesandvaccinationstrategiesinchinaasystematicreview AT jiayizhang comparativeanalysisofhealtheconomicevaluationsfordifferentinfluenzavaccinesandvaccinationstrategiesinchinaasystematicreview AT huijiezhu comparativeanalysisofhealtheconomicevaluationsfordifferentinfluenzavaccinesandvaccinationstrategiesinchinaasystematicreview AT zhibinpeng comparativeanalysisofhealtheconomicevaluationsfordifferentinfluenzavaccinesandvaccinationstrategiesinchinaasystematicreview AT jiandongzheng comparativeanalysisofhealtheconomicevaluationsfordifferentinfluenzavaccinesandvaccinationstrategiesinchinaasystematicreview AT yamingzheng comparativeanalysisofhealtheconomicevaluationsfordifferentinfluenzavaccinesandvaccinationstrategiesinchinaasystematicreview AT haifang comparativeanalysisofhealtheconomicevaluationsfordifferentinfluenzavaccinesandvaccinationstrategiesinchinaasystematicreview |